Peroxisome proliferator-activated receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway

被引:32
作者
Qin, Liang [1 ]
Ren, Ye [1 ]
Chen, An-Min [1 ]
Guo, Feng-Jing [1 ]
Xu, Fei [1 ]
Gong, Chen [2 ]
Cheng, Peng [1 ]
Du, Yu [1 ]
Liao, Hui [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Orthoped, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
关键词
PPAR gamma ligands; vasculogenic mimicry; prostate cancer; VEGF; TUMOR-CELL PLASTICITY; GROWTH-INHIBITION; CHANNEL FORMATION; EXPRESSION; MECHANISMS; ANGIOGENESIS; CARCINOMA; APOPTOSIS; INVASION; PATTERNS;
D O I
10.3892/mmr.2014.2198
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vasculogenic mimicry (VM) describes functional vascular channels composed only of tumor cells and its presence predicts a poor prognosis for patients with prostate cancer. The present study demonstrated that prostate cancer PC-3 cells were able to form a patterned matrix or tubular VM in 3D cultures in vitro and rosiglitazone (RSG), the ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma) and effectively inhibited the formation of VM structures in a dose-and PPAR gamma-dependent manner. In addition, RSG significantly inhibited prostate cancer cell migration and invasion. The inhibitory effect of RSG on VM formation could be at least partially explained by an RSG-driven downregulation of vascular endothelial growth factor (VEGF) levels and phosphorylation of AKT, which is known to be important in VM. Furthermore, the present study highlighted that VEGF and the phosphoinositide 3-kinase/AKT pathway exert a positive feedback regulation in the process of VM formation. These findings reveal new therapeutic potential for PPAR gamma ligands in anti-cancer therapy.
引用
收藏
页码:276 / 282
页数:7
相关论文
共 43 条
[1]   Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells [J].
Basu, GD ;
Pathangey, LB ;
Tinder, TL ;
Gendler, SJ ;
Mukherjee, P .
BREAST CANCER RESEARCH, 2005, 7 (04) :R422-R435
[2]  
Chen WC, 2005, CHINESE MED J-PEKING, V118, P1477
[3]   MMP-2 alters VEGF expression via αVβ3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells [J].
Chetty, Chandramu ;
Lakka, Sajani S. ;
Bhoopathi, Praveen ;
Rao, Jasti S. .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (05) :1081-1095
[4]   Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].
de Bono, Johann Sebastian ;
Oudard, Stephane ;
Ozguroglu, Mustafa ;
Hansen, Steinbjorn ;
Machiels, Jean-Pascal ;
Kocak, Ivo ;
Gravis, Gwenaelle ;
Bodrogi, Istvan ;
Mackenzie, Mary J. ;
Shen, Liji ;
Roessner, Martin ;
Gupta, Sunil ;
Sartor, A. Oliver .
LANCET, 2010, 376 (9747) :1147-1154
[5]   Alternative vascularization mechanisms in cancer -: Pathology and therapeutic implications [J].
Dome, Balazs ;
Hendrix, Mary J. C. ;
Paku, Sandor ;
Tovari, Jozsef ;
Timar, Jozsef .
AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (01) :1-15
[6]   A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry [J].
El Hallani, Soufiane ;
Boisselier, Blandine ;
Peglion, Florent ;
Rousseau, Audrey ;
Colin, Carole ;
Idbaih, Ahmed ;
Marie, Yannick ;
Mokhtari, Karima ;
Thomas, Jean-Leon ;
Eichmann, Anne ;
Delattre, Jean-Yves ;
Maniotis, Andrew J. ;
Sanson, Marc .
BRAIN, 2010, 133 :973-982
[7]   Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy [J].
Fan, Yue-Zu ;
Sun, Wei .
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2010, 2 (04) :117-127
[8]   Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma [J].
Fujita, Megumi ;
Yagami, Tatsurou ;
Fujio, Miki ;
Tohji, Chiaki ;
Takase, Kenkichi ;
Yamamoto, Yasuhiro ;
Sawada, Kyoko ;
Yamamori, Motohiro ;
Okamura, Noboru .
CANCER LETTERS, 2011, 312 (02) :219-227
[9]   PPAR activators inhibit endothelial cell migration by targeting Akt [J].
Goetze, S ;
Eilers, F ;
Bungenstock, A ;
Kintscher, U ;
Stawowy, P ;
Blaschke, F ;
Graf, K ;
Law, RE ;
Fleck, E ;
Gräfe, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (05) :1431-1437
[10]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364